论文部分内容阅读
目的探讨尿激酶(天普络欣,UK)静脉溶栓治疗心肌梗死(AMI)的效果。方法通过采用天普洛欣静脉溶栓治疗50例心肌梗死患者,分析患者的数据及临床疗效。结果 50例患者中,30例患者于发病后6 h内,对其进行静脉溶栓治疗,其再通率大约为86.67%;20例患者于发病6 h之后,12 h之内对其进行静脉溶栓治疗,患者的心肌血管再通率为70.00%,比较差异有统计学意义(P<0.05)。冠脉达到再通标准的有40例,再通率达80.00%;10例患者没有达再通标准。结论心肌梗死患者应尽早进行静脉溶栓治疗,以降低病死率,提高再通成功率。
Objective To investigate the effect of intravenous thrombolytic therapy of urokinase (Tianpuluoxin, UK) on myocardial infarction (AMI). Methods Fifty patients with myocardial infarction were treated with thrombolysis of dayopus injection, and the data and clinical efficacy of the treatment were analyzed. Results Among the 50 patients, 30 patients were treated with intravenous thrombolysis within 6 hours after onset, and the recanalization rate was about 86.67%. Twenty patients underwent intravenous Thrombolytic therapy, the patient’s myocardial recanalization rate was 70.00%, the difference was statistically significant (P <0.05). Coronary re-pass the standard to 40 cases, the recanalization rate of 80.00%; 10 patients did not reach the standard again. Conclusion Patients with myocardial infarction should be treated with intravenous thrombolysis as soon as possible to reduce the mortality and improve the success rate of recanalization.